894 related articles for article (PubMed ID: 8541129)
21. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
[TBL] [Abstract][Full Text] [Related]
22. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography.
Oberholzer PA; Urosevic M; Steinert HC; Dummer R
Dermatology; 2008; 217(4):351-5. PubMed ID: 18799883
[TBL] [Abstract][Full Text] [Related]
23. Heterogenous S-100B protein expression patterns in malignant melanoma and association with serum protein levels.
Bánfalvi T; Udvarhelyi N; Orosz Z; Gergye M; Gilde K; Tímár J
Oncology; 2003; 64(4):374-9. PubMed ID: 12759535
[TBL] [Abstract][Full Text] [Related]
24. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
[TBL] [Abstract][Full Text] [Related]
25. [Neuron-specific enolase (NSE)--a suitable tumor marker in malignant melanoma?].
Hornef S; Lux J; Rassner G
Hautarzt; 1992 Feb; 43(2):77-80. PubMed ID: 1347764
[TBL] [Abstract][Full Text] [Related]
26. Serum S-100 has prognostic significance in malignant melanoma.
Bonfrer JM; Korse CM; Israels SP
Anticancer Res; 1997; 17(4B):2975-7. PubMed ID: 9329579
[TBL] [Abstract][Full Text] [Related]
27. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence?
Schlagenhauff B; Schittek B; Ellwanger U; Stroebel W; Blum A; Schwarz M; Rassner G; Garbe C
Melanoma Res; 2000 Oct; 10(5):451-9. PubMed ID: 11095406
[TBL] [Abstract][Full Text] [Related]
28. [Role of neuron specific enolase and S100 protein in evaluation of brain damage in patients resuscitated from cardiac arrest].
Miao WL; Li HL; Wang HD; Wang J; Liu H; Ren HX; Lin HY
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Dec; 19(12):749-52. PubMed ID: 18093437
[TBL] [Abstract][Full Text] [Related]
29. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
30. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
31. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma.
Hamberg AP; Korse CM; Bonfrer JM; de Gast GC
Melanoma Res; 2003 Feb; 13(1):45-9. PubMed ID: 12569284
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
33. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
34. Neuron specific enolase (NSE) in serum of patients with malignant melanoma.
Wibe E; Paus E; Aamdal S
Cancer Lett; 1990 Jun; 52(1):29-31. PubMed ID: 2354416
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of serum S-100B in malignant melanoma.
Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
[TBL] [Abstract][Full Text] [Related]
36. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke.
Brea D; Sobrino T; Blanco M; Cristobo I; Rodríguez-González R; Rodríguez-Yañez M; Moldes O; Agulla J; Leira R; Castillo J
Clin Chem Lab Med; 2009; 47(12):1513-8. PubMed ID: 19863297
[TBL] [Abstract][Full Text] [Related]
37. Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma.
Acland K; Evans AV; Abraha H; Healy CM; Roblin P; Calonje E; Orchard G; Higgins E; Sherwood R; Russell-Jones R
Br J Dermatol; 2002 May; 146(5):832-5. PubMed ID: 12000380
[TBL] [Abstract][Full Text] [Related]
38. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma.
Mårtenson ED; Hansson LO; Nilsson B; von Schoultz E; Månsson Brahme E; Ringborg U; Hansson J
J Clin Oncol; 2001 Feb; 19(3):824-31. PubMed ID: 11157036
[TBL] [Abstract][Full Text] [Related]
39. [Neuron-specific enolase: a serum marker of clinical progression for metastatic malignant melanoma].
Guo HB; Stoffel-Wagner B; Brennemann W; Springer W; Klingmüller D
J Tongji Med Univ; 1995; 15(1):19-25. PubMed ID: 7783258
[No Abstract] [Full Text] [Related]
40. Neuron-specific enolase--a serum marker for malignant melanoma.
Lorenz J; Dippold W
J Natl Cancer Inst; 1989 Nov; 81(22):1754-5. PubMed ID: 2810389
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
